There are currently no generic versions of Myfortic (mycophenolate sodium). The medication is protected by a patent that is set to expire in April 2017. After this patent expires, several companies could begin making a generic version. Although CellCept and Myfortic both contain mycophenolate, they are not the same medication.
Myfortic® (mycophenolate sodium) is a prescription medication used to prevent kidney transplant rejection. It belongs to a group of drugs known as immunosuppressants.
Myfortic is manufactured by Novartis Pharma Stein AG for Novartis Pharmaceuticals Corporation. At this time, there are no generic versions of Myfortic.
The patent for Myfortic currently expires in April 2017. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Myfortic uses. Once the patent expires, there may be several companies that manufacture a generic Myfortic drug.
No -- mycophenolate is the active ingredient in Myfortic, but is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.
CellCept® (mycophenolate mofetil) and Myfortic both contain mycophenolate, but they are not the same medication. Instead, they contain different forms of the drug. Mycophenolate mofetil (the form found in CellCept) is broken down by the body into mycophenolate sodium (the form found in Myfortic). The body handles these two medicines differently, so they are not directly interchangeable.